Header Logo

Connection

Melody Cobleigh to Breast Neoplasms

This is a "connection" page, showing publications Melody Cobleigh has written about Breast Neoplasms.
Connection Strength

8.211
  1. Comparison of Radiation With or Without Concurrent Trastuzumab for HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy: A Phase III Clinical Trial. J Clin Oncol. 2021 07 20; 39(21):2367-2374.
    View in: PubMed
    Score: 0.560
  2. Baseline Characteristics, Treatment Patterns, and Outcomes in Patients with HER2-Positive Metastatic Breast Cancer by Hormone Receptor Status from SystHERs. Clin Cancer Res. 2020 03 01; 26(5):1105-1113.
    View in: PubMed
    Score: 0.512
  3. Somatic loss of PIK3R1 may sensitize breast cancer to inhibitors of the MAPK pathway. Breast Cancer Res Treat. 2019 Sep; 177(2):325-333.
    View in: PubMed
    Score: 0.496
  4. Central Nervous System Metastasis in Patients with HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from SystHERs. Clin Cancer Res. 2019 04 15; 25(8):2433-2441.
    View in: PubMed
    Score: 0.480
  5. HER2-directed treatment of metastatic breast cancer: unanswered questions. Oncology (Williston Park). 2013 Mar; 27(3):176, 178, 180.
    View in: PubMed
    Score: 0.321
  6. Adjuvant endocrine therapy for breast cancer. Oncology (Williston Park). 2012 Jun; 26(6):541-7, 550, 552 passim.
    View in: PubMed
    Score: 0.305
  7. Other options in the treatment of advanced breast cancer. Semin Oncol. 2011 Jun; 38 Suppl 2:S11-6.
    View in: PubMed
    Score: 0.284
  8. Targeting metastatic and advanced breast cancer. Semin Oncol Nurs. 2007 Feb; 23(1):37-45.
    View in: PubMed
    Score: 0.210
  9. The basal subtype of breast carcinomas may represent the group of breast tumors that could benefit from EGFR-targeted therapies. Breast. 2007 Feb; 16(1):104-7.
    View in: PubMed
    Score: 0.207
  10. The challenging estrogen receptor-negative/ progesterone receptor-negative/HER-2-negative patient: a promising candidate for epidermal growth factor receptor-targeted therapy? Breast J. 2006 Jul-Aug; 12(4):360-2.
    View in: PubMed
    Score: 0.202
  11. Tumor gene expression and prognosis in breast cancer patients with 10 or more positive lymph nodes. Clin Cancer Res. 2005 Dec 15; 11(24 Pt 1):8623-31.
    View in: PubMed
    Score: 0.195
  12. A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol. 2003 Oct; 30(5 Suppl 16):117-24.
    View in: PubMed
    Score: 0.167
  13. Is trastuzumab every three weeks ready for prime time? J Clin Oncol. 2003 Nov 01; 21(21):3900-1.
    View in: PubMed
    Score: 0.167
  14. Impact of the 2018 ACR Supplemental Screening Recommendations on MRI Eligibility in Breast Cancer Survivors. J Am Coll Radiol. 2023 01; 20(1):71-78.
    View in: PubMed
    Score: 0.158
  15. The Phase II MutHER Study of Neratinib Alone and in Combination with Fulvestrant in HER2-Mutated, Non-amplified Metastatic Breast Cancer. Clin Cancer Res. 2022 04 01; 28(7):1258-1267.
    View in: PubMed
    Score: 0.151
  16. Baseline characteristics and first-line treatment patterns in patients with HER2-positive metastatic breast cancer in the SystHERs registry. Breast Cancer Res Treat. 2021 Jul; 188(1):179-190.
    View in: PubMed
    Score: 0.140
  17. Paired tumor sequencing and germline testing in breast cancer management: An experience of a single academic center. Cancer Rep (Hoboken). 2020 12; 3(6):e1287.
    View in: PubMed
    Score: 0.135
  18. Loss of STAT6 leads to anchorage-independent growth and trastuzumab resistance in HER2+ breast cancer cells. PLoS One. 2020; 15(6):e0234146.
    View in: PubMed
    Score: 0.133
  19. Managing menopausal problems. Cancer Treat Res. 2000; 103:1-23.
    View in: PubMed
    Score: 0.129
  20. Trastuzumab-induced cardiac toxicity: Is serial assessment of left ventricular ejection fraction during treatment necessary? Breast J. 2020 05; 26(5):1085-1086.
    View in: PubMed
    Score: 0.127
  21. De Novo Versus Recurrent HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from the SystHERs Registry. Oncologist. 2020 02; 25(2):e214-e222.
    View in: PubMed
    Score: 0.127
  22. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 1999 Sep; 17(9):2639-48.
    View in: PubMed
    Score: 0.126
  23. Hormone replacement therapy and high S phase in breast cancer. JAMA. 1999 Apr 28; 281(16):1528-30.
    View in: PubMed
    Score: 0.123
  24. Can chimerism explain breast/ovarian cancers in BRCA non-carriers from BRCA-positive families? PLoS One. 2018; 13(4):e0195497.
    View in: PubMed
    Score: 0.114
  25. Hormone replacement therapy and nonhormonal control of menopausal symptoms in breast cancer survivors. Cancer Treat Res. 1998; 94:209-30.
    View in: PubMed
    Score: 0.112
  26. Hereditary diffuse gastric cancer and lynch syndromes in a BRCA1/2 negative breast cancer patient. Breast Cancer Res Treat. 2017 Nov; 166(1):315-319.
    View in: PubMed
    Score: 0.109
  27. Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer. Clin Cancer Res. 2017 Oct 01; 23(19):5687-5695.
    View in: PubMed
    Score: 0.108
  28. Cardiovascular Monitoring With Trastuzumab Therapy: How Frequent Is Too Frequent? JAMA Oncol. 2016 Sep 01; 2(9):1123-4.
    View in: PubMed
    Score: 0.102
  29. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol. 1996 May; 14(5):1718-29.
    View in: PubMed
    Score: 0.100
  30. Progression-free survival as surrogate end point for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer. Ann Oncol. 2016 06; 27(6):1029-1034.
    View in: PubMed
    Score: 0.099
  31. Mutations in PIK3CA sensitize breast cancer cells to physiologic levels of aspirin. Breast Cancer Res Treat. 2016 Feb; 156(1):33-43.
    View in: PubMed
    Score: 0.099
  32. Estrogen replacement therapy in breast cancer survivors. A time for change. Breast Cancer Committees of the Eastern Cooperative Oncology Group. JAMA. 1994 Aug 17; 272(7):540-5.
    View in: PubMed
    Score: 0.089
  33. Genetic variant predicts bevacizumab-induced hypertension in ECOG-5103 and ECOG-2100. Br J Cancer. 2014 Sep 09; 111(6):1241-8.
    View in: PubMed
    Score: 0.089
  34. Population pharmacokinetics of trastuzumab emtansine (T-DM1), a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer: clinical implications of the effect of covariates. Cancer Chemother Pharmacol. 2014 Aug; 74(2):399-410.
    View in: PubMed
    Score: 0.088
  35. Breast cancer and fenretinide, an analogue of vitamin A. Leukemia. 1994; 8 Suppl 3:S59-63.
    View in: PubMed
    Score: 0.085
  36. Preliminary results of centralized HER2 testing in ductal carcinoma in situ (DCIS): NSABP B-43. Breast Cancer Res Treat. 2013 Nov; 142(2):415-21.
    View in: PubMed
    Score: 0.084
  37. Phase I/II trial of tamoxifen with or without fenretinide, an analog of vitamin A, in women with metastatic breast cancer. J Clin Oncol. 1993 Mar; 11(3):474-7.
    View in: PubMed
    Score: 0.080
  38. Prognostic and predictive value of tumor vascular endothelial growth factor gene amplification in metastatic breast cancer treated with paclitaxel with and without bevacizumab; results from ECOG 2100 trial. Clin Cancer Res. 2013 Mar 01; 19(5):1281-9.
    View in: PubMed
    Score: 0.080
  39. Impact of exploratory biomarkers on the treatment effect of bevacizumab in metastatic breast cancer. Clin Cancer Res. 2011 Jan 15; 17(2):372-81.
    View in: PubMed
    Score: 0.069
  40. Phase III double-blind, placebo-controlled, prospective randomized trial of adjuvant tamoxifen vs. tamoxifen and fenretinide in postmenopausal women with positive receptors (EB193): an intergroup trial coordinated by the Eastern Cooperative Oncology Group. Med Oncol. 2011 Dec; 28 Suppl 1:S39-47.
    View in: PubMed
    Score: 0.068
  41. ACR appropriateness criteria on postmastectomy radiotherapy expert panel on radiation oncology-breast. Int J Radiat Oncol Biol Phys. 2009 Mar 15; 73(4):997-1002.
    View in: PubMed
    Score: 0.061
  42. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol. 2008 Oct 01; 26(28):4672-8.
    View in: PubMed
    Score: 0.059
  43. Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer. Breast Cancer Res Treat. 2009 May; 115(1):115-21.
    View in: PubMed
    Score: 0.058
  44. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 2008 Apr 10; 26(11):1810-6.
    View in: PubMed
    Score: 0.057
  45. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007 Dec 27; 357(26):2666-76.
    View in: PubMed
    Score: 0.056
  46. Are tri-ethnic low-income women with breast cancer effective teachers of the importance of breast cancer screening to their first-degree relatives? Results from a randomized clinical trial. Breast J. 2007 Jan-Feb; 13(1):19-27.
    View in: PubMed
    Score: 0.052
  47. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol. 2006 Jun 20; 24(18):2786-92.
    View in: PubMed
    Score: 0.050
  48. Genetic testing in an ethnically diverse cohort of high-risk women: a comparative analysis of BRCA1 and BRCA2 mutations in American families of European and African ancestry. JAMA. 2005 Oct 19; 294(15):1925-33.
    View in: PubMed
    Score: 0.048
  49. Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab. Clin Breast Cancer. 2005 Aug; 6(3):240-6.
    View in: PubMed
    Score: 0.047
  50. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol. 2005 Feb 01; 23(4):792-9.
    View in: PubMed
    Score: 0.046
  51. Determination of factors associated with hospitalization in breast cancer survivors. Oncol Nurs Forum. 2004 Nov 16; 31(6):1081-8.
    View in: PubMed
    Score: 0.045
  52. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol. 2005 Jan 20; 23(3):619-29.
    View in: PubMed
    Score: 0.045
  53. Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. J Clin Oncol. 2004 Mar 15; 22(6):1063-70.
    View in: PubMed
    Score: 0.043
  54. A randomized phase II feasibility trial of BMS-275291 in patients with early stage breast cancer. Clin Cancer Res. 2004 Mar 15; 10(6):1971-5.
    View in: PubMed
    Score: 0.043
  55. A case of herceptin cardiotoxicity. Am J Ther. 2004 Jan-Feb; 11(1):74-6.
    View in: PubMed
    Score: 0.042
  56. American Society of Clinical Oncology technology assessment working group update: use of aromatase inhibitors in the adjuvant setting. J Clin Oncol. 2003 Jul 01; 21(13):2597-9.
    View in: PubMed
    Score: 0.041
  57. Predictors of lymph node metastasis in T1 breast carcinoma, stratified by patient age. Breast J. 2002 Nov-Dec; 8(6):349-55.
    View in: PubMed
    Score: 0.039
  58. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002. J Clin Oncol. 2002 Aug 01; 20(15):3317-27.
    View in: PubMed
    Score: 0.039
  59. A randomized phase II pilot trial of adjuvant marimastat in patients with early-stage breast cancer. Ann Oncol. 2002 Aug; 13(8):1220-4.
    View in: PubMed
    Score: 0.039
  60. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002 Feb 01; 20(3):719-26.
    View in: PubMed
    Score: 0.037
  61. Self-reported dietary habits, overall dietary quality and symptomatology of breast cancer survivors: a cross-sectional examination. Breast Cancer Res Treat. 2002 Jan; 71(2):113-23.
    View in: PubMed
    Score: 0.037
  62. Phase II study of vindesine in patients with metastatic breast cancer. Cancer Treat Rep. 1981 Jul-Aug; 65(7-8):659-63.
    View in: PubMed
    Score: 0.036
  63. First-line, single-agent Herceptin(trastuzumab) in metastatic breast cancer: a preliminary report. Eur J Cancer. 2001 Jan; 37 Suppl 1:S25-9.
    View in: PubMed
    Score: 0.035
  64. First-line Herceptin monotherapy in metastatic breast cancer. Oncology. 2001; 61 Suppl 2:37-42.
    View in: PubMed
    Score: 0.035
  65. Reliability and validity of the Functional Assessment of Cancer Therapy-Breast quality-of-life instrument. J Clin Oncol. 1997 Mar; 15(3):974-86.
    View in: PubMed
    Score: 0.026
  66. Tandem peripheral blood progenitor cell transplants as initial therapy for metastatic breast cancer. Biol Blood Marrow Transplant. 1995 Nov; 1(1):40-6.
    View in: PubMed
    Score: 0.024
  67. Should multicentric disease be an absolute contraindication to the use of breast-conserving therapy? Int J Radiat Oncol Biol Phys. 1994 Aug 30; 30(1):49-53.
    View in: PubMed
    Score: 0.022
  68. Treatment of metastatic breast cancer with a split-course high-dose chemotherapy regimen and autologous bone marrow transplantation. J Clin Oncol. 1994 Feb; 12(2):342-6.
    View in: PubMed
    Score: 0.021
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.